GlassScriptPhysician profile
Lynn A Wiens
NPI 1861465916
$20,008.11
in general payments reported to CMS, 2019-2025
40 companies · $3,609 in 2025
The $3,609 reported for 2025 was more than what 80% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,024 · 2020: $1,825 · 2021: $2,080 · 2022: $3,306 · 2023: $4,025 · 2024: $3,138 · 2025: $3,609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $195 · Honoraria: $175 · Consulting Fee: $16.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,386.38 |
| Education | $194.73 |
| Honoraria | $175.00 |
| Consulting Fee | $16.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,855.22 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,813.75 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Csl Behring | $1,736.34 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Regeneron Healthcare Solutions, INC. | $1,637.75 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,606.45 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $1,433.98 | 2020-2025 | Cuvitru, Takhzyro, Eohilia |
| Genentech USA, INC. | $834.08 | 2019-2025 | Xolair |
| Pfizer INC. | $811.05 | 2019-2025 | |
| Alk-Abello, INC | $745.43 | 2019-2024 | Odactra, Grastek, Ragwitek |
| Pharming Healthcare, INC. | $690.69 | 2020-2025 | Ruconest |
| Grifols USA, LLC | $575.91 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Novartis Pharmaceuticals Corporation | $525.77 | 2019-2025 | |
| Amgen INC. | $501.81 | 2022-2025 | Tezspire |
| Kaleo, INC. | $404.08 | 2019-2023 | Auvi-Q |
| Blueprint Medicines Corporation | $380.69 | 2023-2025 | Ayvakit |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Wiens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.